Taysha Gene Therapies, Inc. (TSHA) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Taysha Gene Therapies, Inc. (TSHA) posted $9.77M in revenue for fiscal 2025 (up 17.3% year over year), with a net loss of $109.00M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. has grown revenue from $0 to $9.77M over the last 6 fiscal years. The most recent year was up 17.3%.
Net margin sits at -1115.3%, down 43.7 points year over year. It carries about $50.11M of total debt.
The one thing worth a second look in the filings is debt with negative operating cash flow.
Synthesised from Taysha Gene Therapies, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Taysha Gene Therapies, Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $2.50M | $15.45M | $8.33M | $9.77M |
| Gross profit | — | — | — | — | — | — |
| Net income | $-60.01M | $-174.52M | $-166.01M | $-111.57M | $-89.30M | $-109.00M |
| Net margin | — | — | -6635.3% | -722.1% | -1071.6% | -1115.3% |
Source: Taysha Gene Therapies, Inc. SEC filings (10-K).
Taysha Gene Therapies, Inc.: 2 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Debt with negative operating cash flowCarries $50.1M of debt while last year's operating cash flow was negative ($-93.1M).
- Currently unprofitableThe latest fiscal year was a net loss (net margin -1115.3%).
Explore 6 years of Taysha Gene Therapies, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track TSHA in your portfolio →
Taysha Gene Therapies, Inc. financial history by metric
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Taysha Gene Therapies, Inc. — frequently asked questions
What is Taysha Gene Therapies, Inc.'s revenue?
Taysha Gene Therapies, Inc. (TSHA) reported revenue of $9.77M for fiscal year 2025, up 17.3% from the prior year, according to its SEC filings.
Is Taysha Gene Therapies, Inc. profitable?
No — TSHA reported a net loss of $-109.00M in fiscal 2025.
What is TSHA's P/E ratio?
Taysha Gene Therapies, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Taysha Gene Therapies, Inc. have?
As of fiscal year 2025, TSHA carried roughly $50.11M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Taysha Gene Therapies, Inc.'s market cap?
Taysha Gene Therapies, Inc. (TSHA) has a market capitalization of about $1.62B, based on the latest data in our nightly-refreshed cache.
When does Taysha Gene Therapies, Inc.'s fiscal year end?
TSHA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Taysha Gene Therapies, Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.